TruScreen Half Year Report and Interim Financial Statements

NZX and Media Release 31 January 2017 TruScreen Half Year Report and Interim Financial Statements TruScreen Limited has provided a copy of its 2017 Interim Report for the six months ended 30 September 2016. The report is available for viewing on the company website http://truscreen.com/investor-centre/reports-presentations/. -ENDS- For more information visit www.truscreen.com or contact Martin Dillon, TruScreen Chief Executive Officer, eMail: martindillon@truscreen.com About TruScreen: TruScreen's real time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissue. A sophisticated proprietary algorithm framework distinguishes between normal and abnormal (cancerous and precancerous) tissue to identify precancerous change, or cervical intraepithelial neoplasia (CIN). A Single Use Sensor (SUS) is used for each patient to protect against cross-infection. End CA:00296167 For:TRU Type:INTERIM Time:2017-01-31 12:58:32